A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance
2018
Science Translational Medicine
There is a clinical need for new bronchodilator drugs in asthma, because more than half of asthmatic patients do not receive adequate control with current available treatments. We report that inhibition of metallothionein-2 protein expression in lung tissues causes the increase of pulmonary resistance. Conversely, metallothionein-2 protein is more effective than 2 -agonists in reducing pulmonary resistance in rodent asthma models, alleviating tension in tracheal spirals, and relaxing airway
doi:10.1126/scitranslmed.aam8604
pmid:29437149
fatcat:juuzubyvfbas7meyn3r2zyh26y